User login
Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).
Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.
Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi: 10.1016/j.ypmed.2022.107169
Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).
Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.
Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi: 10.1016/j.ypmed.2022.107169
Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).
Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.
Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi: 10.1016/j.ypmed.2022.107169